The bill modifies existing insurance regulations to eliminate a previous sunset clause that would have allowed mandatory coverage to end on December 31, 2025. By extending this coverage indefinitely, HB 5256 signifies a commitment to pediatric health by addressing the treatment needs of children suffering from these specific neuropsychiatric disorders. It also requires that any related healthcare services administered outside of Rhode Island are covered under certain conditions, ensuring that families can seek treatment even when it necessitates out-of-state services.
Summary
House Bill 5256 mandates that all group health insurance contracts and medical expense policies in Rhode Island provide coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. This bill aims to ensure that families have access to necessary treatments, including intravenous immunoglobin therapy, which may be crucial for affected children. The coverage requirement is applicable for contracts issued, renewed, or delivered on or after January 1, 2023.
Conclusion
Overall, HB 5256 reflects a growing recognition of the need for specialized health coverage for vulnerable populations such as children with neuropsychiatric disorders. The ongoing analysis and subsequent reporting requirements attach an element of accountability to insurance providers, fostering a dialogue about the intersection of healthcare provision and cost management in Rhode Island.
Contention
One notable point of contention may arise from the insurance carriers' obligation to report on the cost-effectiveness of this mandated coverage. Specifically, insurance carriers are tasked with compiling data regarding the financial implications of providing this coverage to the health insurance commissioner. The expected cost-benefit analysis, due by January 1, 2025, will evaluate whether the mandated coverage produces any net savings for carriers and policyholders. This could open discussions around the financial burden on insurers and the potential increases in insurance premiums resulting from this policy.
Insurance: insurers; coverage for certain pediatric autoimmune neuropsychiatric disorders; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406pp.
Extends coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome by removing the sunset date of December 31, 2025, and mandating such coverage.
Removes the sunset provision of all statutory law requiring coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.
An Act to amend and reenact ยงยง 38.2-3418.21 and 38.2-3418.22 of the Code of Virginia, relating to Bureau of Insurance; essential health benefits benchmark plan selection.
A bill for an act relating to health insurance coverage for specified pediatric autoimmune neuropsychiatric disorders and postinfectious autoimmune encephalopathy.
Insurance: insurers; coverage for certain pediatric autoimmune neuropsychiatric disorders; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406pp.
Removes the sunset provision of all statutory law requiring coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.
Extends coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome by removing the sunset date of December 31, 2025, and mandating such coverage.
Human services: medical services; coverage for the prophylaxis, diagnosis, and treatment of certain pediatric autoimmune neuropsychiatric disorders; require. Amends 1939 PA 280 (MCL 400.1 - 400.119b) by adding sec. 109v.